Top

Open Access 25-09-2024 | Vitiligo | REVIEW

Post-translational modification in the pathogenesis of vitiligo

Authors: Lu Lu, Huimin He, Jindi Feng, Zhonghui Hu, Shiyu Zhang, Lu Yang, Yuehua Liu, Tao Wang

Abstract

Vitiligo is a chronic dermatological condition marked by the loss of skin pigmentation. Its complex etiology involves multiple factors and has not been completely elucidated. Protein post-translational modification pathways have been proven to play a significant role in inflammatory skin diseases, yet research in the context of vitiligo remains limited. This review focuses on the role of post-translational modifications in vitiligo pathogenesis, especially their impact on cellular signaling pathways related to immune response and melanocyte survival. Current therapeutic strategies targeting these pathways are discussed, emphasizing the potential for novel treatments in vitiligo management.

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84. https://doi.org/10.1016/S0140-6736(14)60763-7.CrossRefPubMed

Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236:571–92. https://doi.org/10.1159/000506103.CrossRefPubMed

Liu J, Qian C, Cao X. Post-translational modification control of innate immunity. Immunity. 2016;45:15–30. https://doi.org/10.1016/j.immuni.2016.06.020.CrossRefPubMed

Yang L, Yan Y. Emerging roles of post-translational modifications in skin diseases: current knowledge, challenges and future perspectives. J Inflamm Res. 2022;15:965–75. https://doi.org/10.2147/JIR.S339296.CrossRefPubMedPubMedCentral

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402. https://doi.org/10.1038/s41392-021-00791-1.CrossRefPubMedPubMedCentral

Ardito F, Giuliani M, Perrone D, Troiano G, Lo ML. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med. 2017;40:271–80. https://doi.org/10.3892/ijmm.2017.3036.CrossRefPubMedPubMedCentral

D’Mello SAN, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17:1144. https://doi.org/10.3390/ijms17071144.CrossRefPubMedPubMedCentral

Goding CR, Arnheiter H. MITF—the first 25 years. Genes Dev. 2019;33:983–1007. https://doi.org/10.1101/gad.324657.119.CrossRefPubMedPubMedCentral

Yardman-Frank JM, Fisher DE. Skin pigmentation and its control: from ultraviolet radiation to stem cells. Exp Dermatol. 2021;30:560–71. https://doi.org/10.1111/exd.14260.CrossRefPubMed

10.

Sassone-Corsi P. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012;4:a011148–a011148. https://doi.org/10.1101/cshperspect.a011148.CrossRefPubMedPubMedCentral

11.

Busca R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 2000;19:2900–10. https://doi.org/10.1093/emboj/19.12.2900.CrossRefPubMedPubMedCentral

12.

Estrada C, Mirabal-Ortega L, Méry L, Dingli F, Besse L, Messaoudi C, et al. MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells. Commun Biol. 2022;5:101. https://doi.org/10.1038/s42003-022-03049-w.CrossRefPubMedPubMedCentral

13.

Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000;14:301–12.CrossRefPubMedPubMedCentral

14.

Saha B, Singh SK, Sarkar C, Bera R, Ratha J, Tobin DJ, et al. Activation of the Mitf promoter by lipid-stimulated activation of p38-stress signalling to CREB. Pigment Cell Res. 2006;19:595–605. https://doi.org/10.1111/j.1600-0749.2006.00348.x.CrossRefPubMed

15.

Lan C-CE, Chen G-S, Chiou M-H, Wu C-S, Chang C-H, Yu H-S. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo: FK506 promotes melanocyte and melanoblast proliferation. Br J Dermatol. 2005;153:498–505. https://doi.org/10.1111/j.1365-2133.2005.06739.x.CrossRefPubMed

16.

Seneschal J, Duplaine A, Maillard H, Passeron T, Andreu N, Lassalle R, et al. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J Investig Dermatol. 2021;141:1728–34. https://doi.org/10.1016/j.jid.2020.12.028.CrossRefPubMed

17.

Mamat N, Lu XY, Kabas M, Aisa HA. Potential anti-vitiligo properties of cynarine extracted from Vernonia anthelmintica (L.) Willd. Int J Mol Med. 2018;42:2665–75. https://doi.org/10.3892/ijmm.2018.3861.CrossRefPubMedPubMedCentral

18.

Moon SY, Akter K-M, Ahn M-J, Kim KD, Yoo J, Lee J-H, et al. Fraxinol stimulates melanogenesis in B16F10 mouse melanoma cells through CREB/MITF signaling. Molecules. 2022;27. https://doi.org/10.3390/molecules27051549.

19.

Yoon J-H, Youn K, Jun M. Discovery of pinostrobin as a melanogenic agent in cAMP/PKA and p38 MAPK signaling pathway. Nutrients. 2022;14. https://doi.org/10.3390/nu14183713.

20.

Kim M, Jeon K, Shin S, Yoon S, Kim H, Kang HY, et al. Melanogenesis-promoting effect of Cirsium japonicum flower extract in vitro and ex vivo. Int J Cosmet Sci. 2021;43:703–14. https://doi.org/10.1111/ics.12746.CrossRefPubMed

21.

Ahn M-J, Hur S-J, Kim E-H, Lee SH, Shin JS, Kim M-K, et al. Scopoletin from Cirsium setidens increases melanin synthesis via CREB phosphorylation in B16F10 cells. Korean J Physiol Pharmacol. 2014;18:307–11. https://doi.org/10.4196/kjpp.2014.18.4.307.CrossRefPubMedPubMedCentral

22.

Wang HM, Qu LQ, Ng JPL, Zeng W, Yu L, Song LL, et al. Natural Citrus flavanone 5-demethylnobiletin stimulates melanogenesis through the activation of cAMP/CREB pathway in B16F10 cells. Phytomedicine. 2022;98:153941. https://doi.org/10.1016/j.phymed.2022.153941.CrossRefPubMed

23.

Moon KM, Yang J-H, Lee M-K, Kwon E-B, Baek J, Hwang T, et al. Maclurin exhibits antioxidant and anti-tyrosinase activities, suppressing melanogenesis. Antioxidants. 2022;11:1164. https://doi.org/10.3390/antiox11061164.CrossRefPubMedPubMedCentral

24.

Hwang YS, Oh SW, Park S-H, Lee J, Yoo JA, Kwon K, et al. Melanogenic effects of maclurin are mediated through the activation of cAMP/PKA/CREB and p38 MAPK/CREB signaling pathways. Oxid Med Cell Longev. 2019;2019:9827519. https://doi.org/10.1155/2019/9827519.CrossRefPubMedPubMedCentral

25.

Yin L, Pang G, Niu C, Habasi M, Dou J, Aisa HA. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med. 2018;41:3727–35. https://doi.org/10.3892/ijmm.2018.3529.CrossRefPubMed

26.

Zang D, Niu C, Lu X, Aisa HA. A novel furocoumarin derivative, 5-((diethylamino)me-13 thyl)-3-phenyl-7H-furo [3,2-g] chromen-7-one upregulates melanin synthesis via the activation of cAMP/PKA and MAPKs signal pathway: in vitro and in vivo study. Int J Mol Sci. 2022;23. https://doi.org/10.3390/ijms232214190.

27.

Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125. https://doi.org/10.3389/fimmu.2021.790125.CrossRefPubMedPubMedCentral

28.

Azzolino V, Zapata L, Garg M, Gjoni M, Riding RL, Strassner JP, et al. Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. J Investig Dermatol. 2021;141:182-184.e1. https://doi.org/10.1016/j.jid.2020.04.027.CrossRefPubMed

29.

Chen X, Guo W, Chang Y, Chen J, Kang P, Yi X, et al. Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. Free Radical Biol Med. 2019;139:80–91. https://doi.org/10.1016/j.freeradbiomed.2019.05.011.CrossRef

30.

Lu M-C, Ji J-A, Jiang Z-Y, You Q-D. The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36:924–63. https://doi.org/10.1002/med.21396.CrossRefPubMed

31.

Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24:10941–53. https://doi.org/10.1128/MCB.24.24.10941-10953.2004.CrossRefPubMedPubMedCentral

32.

Gęgotek A, Skrzydlewska E. The role of transcription factor Nrf2 in skin cells metabolism. Arch Dermatol Res. 2015;307:385–96. https://doi.org/10.1007/s00403-015-1554-2.CrossRefPubMedPubMedCentral

33.

Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T, et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol. 2014;134:2221–30. https://doi.org/10.1038/jid.2014.152.CrossRefPubMed

34.

Iniaghe LO, Krafft PR, Klebe DW, Omogbai EKI, Zhang JH, Tang J. Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage. Neurobiol Dis. 2015;82:349–58. https://doi.org/10.1016/j.nbd.2015.07.001.CrossRefPubMedPubMedCentral

35.

Na H-K, Surh Y-J. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol. 2008;46:1271–8. https://doi.org/10.1016/j.fct.2007.10.006.CrossRefPubMed

36.

Zhu Y, Wang S, Lin F, Li Q, Xu A. The therapeutic effects of EGCG on vitiligo. Fitoterapia. 2014;99:243–51. https://doi.org/10.1016/j.fitote.2014.08.007.CrossRefPubMed

37.

Hu W, Zhang L, Lin F, Lei J, Zhou M, Xu A. Topical epigallocatechin-3-gallate in the treatment of vitiligo. Australas J Dermatol. 2021;62:e404–7. https://doi.org/10.1111/ajd.13612.CrossRefPubMed

38.

Hu W, Jin R, Lin F, Lei J, Ma Y, Xu A-E. Repigmentation in two patients with vitiligo on AcEGCG 0.5% cream. Clin Exp Dermatol. 2022;47:1760–1. https://doi.org/10.1111/ced.15211.CrossRefPubMed

39.

Jalalmanesh S, Mansouri P, Rajabi M, Monji F. Therapeutic effects of turmeric topical cream in vitiligo: a randomized, double-blind, placebo-controlled pilot study. J Cosmetic Dermatol. 2022;21:4454–61. https://doi.org/10.1111/jocd.14814.CrossRef

40.

Asawanonda P, Klahan S-O. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. Photomed Laser Surg. 2010;28:679–84. https://doi.org/10.1089/pho.2009.2637.CrossRefPubMed

41.

Arowojolu OA, Orlow SJ, Elbuluk N, Manga P. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol. 2017;26:637–44. https://doi.org/10.1111/exd.13350.CrossRefPubMedPubMedCentral

42.

Zeyen L, Seternes OM, Mikkola I. Crosstalk between p38 MAPK and GR signaling. IJMS. 2022;23:3322. https://doi.org/10.3390/ijms23063322.CrossRefPubMedPubMedCentral

43.

Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J. 2012;26:4805–20. https://doi.org/10.1096/fj.12-216382.CrossRefPubMed

44.

Ezzedine K, Whitton M, Pinart M. Interventions for vitiligo. JAMA. 2016;316:1708. https://doi.org/10.1001/jama.2016.12399.CrossRefPubMed

45.

Dey A, Lane DP, Verma CS. Modulating the p53 pathway. Semin Cancer Biol. 2010;20:3–9. https://doi.org/10.1016/j.semcancer.2010.02.004.CrossRefPubMed

46.

Becatti M, Prignano F, Fiorillo C, Pescitelli L, Nassi P, Lotti T, et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxid Redox Signal. 2010;13:1309–21. https://doi.org/10.1089/ars.2009.2779.CrossRefPubMed

47.

Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon M-L, et al. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013;14:1294–301. https://doi.org/10.1038/ni.2744.CrossRefPubMed

48.

Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases. Front Immunol. 2021;12:652191. https://doi.org/10.3389/fimmu.2021.652191.CrossRefPubMedPubMedCentral

49.

Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang SC, Marquardt N, et al. CD49a expression defines tissue-resident CD8 + T cells poised for cytotoxic function in human skin. Immunity. 2017;46:287–300. https://doi.org/10.1016/j.immuni.2017.01.009.CrossRefPubMedPubMedCentral

50.

Boniface K, Seneschal J. Vitiligo as a skin memory disease: the need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Exp Dermatol. 2019;28:656–61. https://doi.org/10.1111/exd.13879.CrossRefPubMed

51.

Willemsen M, Linkutė R, Luiten RM, Matos TR. Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma. Pigment Cell Melanoma Res. 2019;32:612–22. https://doi.org/10.1111/pcmr.12803.CrossRefPubMedPubMedCentral

52.

Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133–45. https://doi.org/10.1172/JCI16432.CrossRefPubMedPubMedCentral

53.

Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T Cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176:640–51. https://doi.org/10.4049/jimmunol.176.1.640.CrossRefPubMed

54.

Patra S, Khaitan BK, Sharma VK, Khanna N. A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive nonsegmental vitiligo. J Am Acad Dermatol. 2021;85:728–9. https://doi.org/10.1016/j.jaad.2019.03.025.CrossRefPubMed

55.

Jawade S, Saoji V, Madke B, Singh A. Comparison of oral azathioprine and oral mini pulse steroid in the treatment of vitiligo: an open-label randomized controlled trial. Indian J Dermatol. 2023;68:591–7. https://doi.org/10.4103/ijd.ijd_865_22.CrossRefPubMed

56.

Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20:156–74. https://doi.org/10.1038/s41580-018-0081-3.CrossRefPubMed

57.

Yang Y, Liu Y, Wang Y, Chao Y, Zhang J, Jia Y, et al. Regulation of SIRT1 and its roles in inflammation. Front Immunol. 2022;13:831168. https://doi.org/10.3389/fimmu.2022.831168.CrossRefPubMedPubMedCentral

58.

Becatti M, Fiorillo C, Barygina V, Cecchi C, Lotti T, Prignano F, et al. SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival. J Cell Mol Med. 2014;18:514–29. https://doi.org/10.1111/jcmm.12206.CrossRefPubMedPubMedCentral

59.

Cao C, Lu S, Kivlin R, Wallin B, Card E, Bagdasarian A, et al. SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes. J Cell Mol Medi. 2009;13:3632–43. https://doi.org/10.1111/j.1582-4934.2008.00453.x.CrossRef

60.

Brahmbhatt HD, Gupta R, Gupta A, Rastogi S, Misri R, Mobeen A, et al. The long noncoding RNA MALAT1 suppresses miR-211 to confer protection from ultraviolet-mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1*. Br J Dermatol. 2021;184:1132–42. https://doi.org/10.1111/bjd.19666.CrossRefPubMed

61.

Diao Z, Ji Q, Wu Z, Zhang W, Cai Y, Wang Z, et al. SIRT3 consolidates heterochromatin and counteracts senescence. Nucleic Acids Res. 2021;49:4203–19. https://doi.org/10.1093/nar/gkab161.CrossRefPubMedPubMedCentral

62.

Yi X, Guo W, Shi Q, Yang Y, Zhang W, Chen X, et al. SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo. Theranostics. 2019;9:1614–33. https://doi.org/10.7150/thno.30398.CrossRefPubMedPubMedCentral

63.

Nie X-J, Hao B-Z, Zhang B-L, Li Y-Y. GATA3 ameliorates melanocyte injuries in vitiligo through SIRT3-mediated HMGB1 deacetylation. J Dermatol. 2023;50:472–84. https://doi.org/10.1111/1346-8138.16634.CrossRefPubMed

64.

Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20:1242–53. https://doi.org/10.1038/nm.3739.CrossRefPubMed

65.

Yuan X, Meng D, Cao P, Sun L, Pang Y, Li Y, et al. Identification of pathogenic genes and transcription factors in vitiligo. Dermatol Ther. 2019;32. https://doi.org/10.1111/dth.13025.

66.

Wang P, Li Y, Nie H, Zhang X, Shao Q, Hou X, et al. The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. J Dermatol Sci. 2016;84:40–9. https://doi.org/10.1016/j.jdermsci.2016.07.006.CrossRefPubMed

67.

Li L, Xie Z, Qian X, Wang T, Jiang M, Qin J, et al. Identification of a potentially functional circRNA-miRNA-mRNA regulatory network in melanocytes for investigating pathogenesis of vitiligo. Front Genet. 2021;12:663091. https://doi.org/10.3389/fgene.2021.663091.CrossRefPubMedPubMedCentral

68.

Fukuda K. Networks of CD8+ T cell response activation in melanoma and vitiligo. Front Immunol. 2022;13:866703. https://doi.org/10.3389/fimmu.2022.866703.CrossRefPubMedPubMedCentral

69.

Dani P, Patnaik N, Singh A, Jaiswal A, Agrawal B, Kumar AA, et al. Association and expression of the antigen-processing gene PSMB8, coding for low-molecular-mass protease 7, with vitiligo in North India: case-control study. Br J Dermatol. 2018;178:482–91. https://doi.org/10.1111/bjd.15391.CrossRefPubMed

70.

Zhu Y, Wang S, Xu A. A mouse model of vitiligo induced by monobenzone. Exp Dermatol. 2013;22:499–501. https://doi.org/10.1111/exd.12184.CrossRefPubMed

71.

van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011;131:1240–51. https://doi.org/10.1038/jid.2011.16.CrossRefPubMed

72.

Celen AB, Sahin U. Sumoylation on its 25th anniversary: mechanisms, pathology, and emerging concepts. FEBS J. 2020;287:3110–40. https://doi.org/10.1111/febs.15319.CrossRefPubMed

73.

Wang Y, Dasso M. SUMOylation and deSUMOylation at a glance. J Cell Sci. 2009;122:4249–52. https://doi.org/10.1242/jcs.050542.CrossRefPubMedPubMedCentral

74.

Zhou M, Lin F, Xu W, Jin R, Xu A. Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep. 2018;18:3469–75. https://doi.org/10.3892/mmr.2018.9299.CrossRefPubMed

75.

Eichler J. Protein glycosylation. Curr Biol. 2019;29:R229–31. https://doi.org/10.1016/j.cub.2019.01.003.CrossRefPubMed

76.

Carlie G, Ntusi NBA, Hulley PA, Kidson SH. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol. 2003;149:707–17. https://doi.org/10.1046/j.1365-2133.2003.05577.x.CrossRefPubMed

Title: Post-translational modification in the pathogenesis of vitiligo
Authors: Lu Lu
Huimin He
Jindi Feng
Zhonghui Hu
Shiyu Zhang
Lu Yang
Yuehua Liu
Tao Wang
Publication date: 25-09-2024
Publisher: Springer US
Keyword: Vitiligo
Published in: Immunologic Research
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-024-09545-x

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Post-translational modification in the pathogenesis of vitiligo

Abstract

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Please log in to get access to this content